pre-IPO PHARMA

COMPANY OVERVIEW

Aerami is a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare cardiopulmonary conditions. Aerami’s mission-driven approach to product development draws seeks to help patients live longer and live better by combining precision medicines and advanced administration platforms to support ease-of-use and quality-of-life.


LOCATION


THERAPEUTIC AREAS


WEBSITE

https://aerami.com


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


Jun 1, 2023

Aerami Therapeutics Appoints Joshua Ziel as COO and Interim CEO and Expands Management Team as Lead Asset AER-901 (inhaled imatinib) Advances Toward Phase 2 in Pulmonary Hypertension


May 24, 2023

Aerami Therapeutics Announces Pharmacokinetic Data Demonstrating the Potential of AER-901 (Inhaled Imatinib) to Achieve Therapeutic Levels at Low Inhaled Doses for Treatment of Pulmonary Hypertension


May 11, 2023

Aerami Therapeutics to Present Pharmacokinetic Data Supporting AER-901 (Inhaled Imatinib) for Pulmonary Hypertension at the 2023 American Thoracic Society (ATS) International Conference


May 5, 2023

Aerami Therapeutics Mourns the Sudden Loss of Chief Executive Officer Lisa Yañez


Apr 3, 2023

Aerami Therapeutics to Host Virtual Investor Day with Leading Experts in Pulmonary Hypertension as AER-901 (Inhaled Imatinib) Advances Toward Phase 2


For More Press Releases


Google Analytics Alternative